

Development and prioritisation of policy recommendations for medication safety improvement for intensive care units: a European Association of Hospital Pharmacists Special Interest Group Delphi Study

Moninne Howlett ^{1,2}, Suzanne McCarthy ³, Virginia Silvari ^{3,4}, Bryony Dean Franklin ^{5,6}, Raisa Laaksonen ⁷, On behalf of the EAHP Special Interest Group for the investigation of medication errors in intensive care units

For numbered affiliations see end of article.

Correspondence to

Dr Moninne Howlett,
Pharmacy/Digital Health,
Children's Health
Ireland, Dublin, Ireland;
moninnehowlett@gmail.com

MH and SM are joint first authors.

Received 14 December 2023
Accepted 12 March 2024

EAHP Statement 4: Clinical Pharmacy Services. EAHP Statement 5: Patient Safety and Quality Assurance.



© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Howlett M, McCarthy S, Silvari V, et al. *Eur J Hosp Pharm* Epub ahead of print: [please include Day Month Year]. doi:10.1136/ejhp-2023-004065

ABSTRACT

Objectives Medication errors (MEs) are a leading cause of morbidity and mortality in the healthcare system. Patients admitted to intensive care units (ICUs) are potentially more susceptible to MEs due to severity of illness, the complexity of treatments they receive and the challenging nature of the ICU setting. The European Association of Hospital Pharmacists established a Special Interest Group (SIG) to undertake a programme of work to develop and prioritise recommendations to support medication safety improvement in ICUs across Europe.

Methods Initial policy recommendations for medication safety within the ICU environment were developed following reviews of the literature and engagement with relevant stakeholders. A Delphi panel of 21 members of the SIG, that comprised healthcare professionals (HCPs) with expertise in ICU and/or medication safety, was convened in 2022. We conducted two rounds using a modified Delphi technique whereby participants anonymously ranked on a 9-point Likert Scale the policy recommendations according to their priority for implementation.

Results In total, 32 policy recommendations were developed. In Delphi Round 1, 19 HCPs participated; consensus was achieved on most recommendations and partial consensus on six. In Delphi Round 2, 18 HCPs participated. After two Delphi rounds, consensus was achieved on all 32 recommendations. All recommendations were considered 'high priority' except one that was considered 'medium priority'.

Conclusions Through this study it was possible to develop and prioritise evidence-based policy recommendations to enhance medication safety, which may contribute to reducing MEs in ICUs across Europe. All recommendations were considered 'high priority' for implementation except one, indicating the perceived value of these recommendations in improving medication safety through preventing MEs in ICUs.

INTRODUCTION

Medication errors (MEs) are a leading cause of morbidity and mortality in the healthcare system.¹ Patients admitted to intensive care units

(ICUs) are potentially more susceptible to MEs due to the complexity and intensity of treatments they receive.² Previous studies have identified risk factors contributing towards MEs and reported on strategies that could prevent them.^{3,4} To support individual hospitals and health organisations in ME risk mitigation, the European Association of Hospital Pharmacists (EAHP) established a Special Interest Group (SIG) that set out to develop a set of recommendations for reducing MEs in European ICUs. The body of work comprised four work packages; the first of these was two literature reviews to: (1) Determine the prevalence of MEs, identify potential sources, causes and contributing factors to MEs; and (2) Identify prevention strategies for improving medication safety in the ICU setting.⁵ Formal systematic reviews or comparison of the evidence base supporting these strategies was beyond the scope of the available resources.

The second work package, an e-survey, was conducted with healthcare professionals (HCPs) working in ICUs to identify the medication safety practices most commonly used, or planned for implementation, in ICUs (submitted for publication). The third work package involved focus group discussions with ICU and medication safety HCPs to explore patient safety culture and advancement of medication safety, and the factors influencing implementation of ME prevention strategies in ICUs across Europe (submitted for publication).

This study describes the fourth work package, the aim of which was to use the findings from the three other work packages to develop and prioritise a list of policy recommendations to support medication safety improvement in ICUs across Europe.

METHODS

Study design

A modified Delphi technique, a methodology that uses a panel of experts to achieve consensus in a clearly defined and systematic manner, was employed by the EAHP SIG to develop and prioritise the list of policy recommendations.

This technique has commonly been used to produce recommendations, including best practice and international patient safety recommendations, where available evidence is lacking or unavailable.⁶

The classical Delphi technique uses a series of questionnaires issued to an expert panel in an iterative manner. A summary of results from individual rounds is provided as anonymous feedback in subsequent rounds, with the aim of converging opinion and reaching consensus.⁶ The term 'modified' Delphi has been applied where face-to-face or online meetings, in tandem with the iterative rounds of consensus, are used. Other modifications include a research team, rather than an expert panel, defining the issues requiring consensus during the initial phase of the process.⁶ For this study, the research team—a subgroup of the SIG—undertook development of the initial list of policy recommendations based on the earlier phases of this study as described above. This group was comprised of seven pharmacists from different European countries, of whom three were actively working in university hospital ICUs, one was a medication safety pharmacist, and three were academic pharmacists with expertise in medication safety. A further modification from the classical Delphi technique was that we conducted the first consensus round during an online meeting in place of distributing the questionnaire to the panel members separately.

For the subsequent stages of the study, all members of the EAHP SIG (n=21) were invited to participate as members of the expert Delphi panel. As part of their selection for the SIG, each member was working within ICUs and/or working as medication safety experts and therefore could be considered experts and eligible to participate in the panel. The SIG membership comprised a diverse group of HCPs from 13 European countries within northern, southern and western European regions. 16 members had a pharmacy background, 4 had a medical background and 1 a nursing background; 17 were women. This study is reported according to Jünger *et al*'s recommended 'Guidance on Conducting and Reporting Delphi Studies (CREDES)'.⁷

Ethical considerations

Participation by the panel of experts was voluntary and confidential and no incentives were offered. Each SIG member received an email with a cover letter and a participant information sheet. Participants were also informed that submission of their responses via the online survey tool would be considered as proof of informed consent to participate. Although anonymity is commonly preserved in Delphi studies, this was not possible in this study as participants were known to each other through their SIG membership. However, the identities of individual participants who opted to participate was not known and responses were submitted anonymously into a General Data Protection Regulation compliant online survey tool (easy-feedback.com).

Development of recommendations and Delphi consensus processes

Stage 1: Identification of recommendations

The following sources of information, as provided by earlier phases of the SIG work packages, were used to develop the initial list of the policy recommendations to be presented to the Delphi panel:

- ▶ ME prevention strategies used to improve medication safety in the ICU environment as identified through the literature review;^{5 8–28}
- ▶ ME prevention strategies both currently in use and being planned in ICUs across Europe as identified through the conducted survey; and
- ▶ Perceptions of patient safety, medication safety, and experiences of ME prevention strategies as identified from the focus group discussions.

The initial list of policy recommendations was categorised and agreed on by the SIG subgroup prior to commencement of Stage 2.

Stage 2: Iterative consensus rounds

A series of iterative consensus rounds were commenced in October 2022, with prior agreement that a maximum of three rounds would be held. The online survey tool (easy-feedback.com) was used for recording the responses. The level of priority of each recommendation was scored using a 9-point Likert scale where a score of 1 indicated 'definitely not a priority' and a score of 9 indicated 'a key priority'. Additional guidance or specific criteria for prioritisation were not provided.

In addition to the Likert scale score for each recommendation, participants were also invited to record any comments on individual recommendations within a dedicated section on the online survey. These comments provided a better understanding of the rationale behind the responses provided at each round and they could be used to modify the recommendations for future rounds as appropriate.

Anonymous responses were downloaded for further analysis using Microsoft Excel (V.2016 or newer). The median and IQR for each recommendation was calculated and the results analysed for the degree of consensus. The following predetermined consensus definitions were applied:²⁹

- ▶ 'Consensus' was considered to exist if the IQR of the participants' responses fell within any 3-point range.
- ▶ 'Disagreement' was considered to exist if the IQR spanned both the 1–3 range and the 7–9 range.
- ▶ If neither consensus nor disagreement existed, 'Partial Agreement' was considered to have occurred.

Where consensus existed, it was considered that the recommendation was a 'high priority' if the median score was within the 7–9 range, a 'low priority' if it was within the 1–3 range and a 'medium priority' if it was within the 4–6 range.

After each round, feedback was provided to all panel members which included the distribution of the panel's response and the list of comments.

Delphi Panel Round 1

All 21 members of the SIG received an invitation to participate in Delphi Round 1. A virtual presentation describing the process for achieving consensus in an iterative manner was delivered to the participants. They were then presented with a brief description of each recommendation as determined in Stage 1. To allow panel members to familiarise themselves with the recommendations, the complete list was sent to all members of the SIG in advance of the meeting.

A link to the online survey was provided in an email during the meeting and the participants were instructed that they could submit their responses either during or after the meeting. It was also reiterated that participants did not need to conform to the group view. In addition, each individual

Table 1 The consensus received for, and the priority given to, the policy recommendations in Delphi Round 1 by the Delphi panel of experts (n=19)*

Category	No.	Recommendation	Median (Q1–Q3; IQR)	Consensus (priority)
Organisational safety culture and working environment	1	Create and maintain an open, transparent and non-hierarchical 'no blame' culture supported by the ICU management to support staff in identifying, sharing, reporting and learning from incidents and near misses.	9 (9–9;0)	Consensus (high)
	2	Implement an effective system to support the reporting of (medication-related) incidents and near misses, including mechanisms to provide feedback on reports to ICU staff.	8 (8–9;1)	Consensus (high)
	3	Undertake routine, systematic and multidisciplinary review of all ICU-related incident reports to identify medication safety areas of risk, opportunities for improvement and provide feedback to ICU staff, for example, use of risk huddles.	8 (8–9;1)	Consensus (high)
	4	Nominate a Medication Safety Lead within the ICU setting to work closely with the organisational Medication Safety Officer (or equivalent) where such a role exists on the implementation and promotion of medication error prevention strategies.	6 (6–8;2)	Consensus (medium)
	5	Undertake regular audits and self-assessment questionnaires, including measurement of patient safety climate in the ICU to monitor medication safety within the ICU.	7 (5–8;3)	Partial consensus (high)
	6	Ensure adequate budget allocation to support sustained improvements in medication safety, including investment in human resources and appropriate technology in the ICU setting.	8 (6–9;3)	Partial consensus (high)
	7	Ensure a safe working environment is provided for ICU staff to practise in a safe and efficient manner, for example, adequate lighting, avoidance of interruptions.	8 (7–9;2)	Consensus (high)
Technology	8	Implement automated dispensing cabinets for the storage of medications in the ICU.	6 (4–7;3)	Partial consensus (medium)
	9	Replace paper-based prescriptions with electronic prescribing systems, for example, computerised physician order entry, with associated clinical decision support appropriate to the ICU setting.	9 (7.75–9;1.25)	Consensus (high)
	10	Implement the use of bar-coded medication administration to reduce medication administration errors and support complete documentation.	7 (6–8;2)	Consensus (high)
	11	Administer all medication infusions via programmable infusion pumps using 'Dose Error Reduction Software' or 'Smart-pumps', which contain a complete and regularly reviewed and updated drug library.	8 (6–8;2)	Consensus (high)
	12	Ensure policies are in place to reduce workarounds and over-rides in the use of implemented technology, for example, bypassing smart-pump drug libraries, bar code medication administration workarounds and automated dispensing cabinet over-rides.	7 (6–8;2)	Consensus (high)
	13	Identify and optimise all opportunities to integrate existing and future systems with the aim of providing 'closed loop' medication management, supporting the 'five rights' of medication administration.	7 (5–8;3)	Partial consensus (high)
	14	Provide dedicated resources to facilitate the implementation, optimisation, maintenance and regular updates to all systems involved in medication management within the ICU.	8 (7–9;2)	Consensus (high)
Clinical pharmacy	15	Provide a dedicated and specialised clinical pharmacy service to the ICU at a staffing level sufficient to ensure regular review and verification of all medications, attendance at multidisciplinary rounds and input into the development of policies, procedures and guidelines.	9 (8–9;1)	Consensus (high)
	16	Adopt formal antimicrobial stewardship with multidisciplinary input to ensure appropriate use of antimicrobials and reduce antimicrobial resistance.	9 (8–9;1)	Consensus (high)
Education and training	17	Provide staff with protected time during working hours and access to a range of education and training opportunities in safe medication use to include new staff from all disciplines, new equipment/medications, refresher training and competency assessment.	8 (7–9;2)	Consensus (high)
Intravenous medication management	18	Standardise and reduce the range of available/recommended medication infusion concentrations.	9 (8–9;1)	Consensus (high)
	19	Provide supporting protocols and guidelines on preparation of intravenous medications as appropriate to the setting and availability of 'ready-to-administer' infusion solutions.	9 (8–9;1)	Consensus (high)
	20	Minimise 'bedside' preparation of intravenous medications and replace with procured and centrally prepared 'ready-to-administer' or 'ready-to-use' medications wherever possible.	8 (7–9;2)	Consensus (high)
	21	Ensure ease of access to information on intravenous compatibilities.	8 (7–9;2)	Consensus (high)
	22	Ensure processes are in place to support safe intravenous medication administration to include: appropriate labelling of medications and administration lines using targeted risk reduction strategies, for example, use of colours, TALLman lettering; administration line checks; infusion pump checks.	8 (7–9;2)	Consensus (high)
High-risk medication management	23	Maintain a high-risk medication list that is reviewed regularly and is context-specific, for example, paediatrics, with a robust set of associated risk mitigation processes for all stages of the medication use process.	7 (6–8;2)	Consensus (high)
	24	Ensure targeted and risk-assessed organisational policies and procedures are in place to support checking procedures for the preparation and administration of high-risk medications, for example, items requiring independent double-checking, specific labelling requirements.	8 (7–9;2)	Consensus (high)

Continued

Table 1 Continued

Category	No.	Recommendation	Median (Q1–Q3; IQR)	Consensus (priority)
Medication history and reconciliation	25	Employ standardised procedures, including patient, family and carer involvement as appropriate, to obtain and document an accurate and complete list (best possible medication history) of each patient's current medication on admission to the ICU.	8 (7–9;2)	Consensus (high)
	26	Implement a formal and thorough medication reconciliation process on both admission to, and discharge from, the ICU to ensure accurate and comprehensive medication information is communicated consistently.	8 (7–9;2)	Consensus (high)
	27	Promote interdisciplinary communication across entire medication use process, using a range of mechanisms and structures, for example, handover procedures and documentation, multidisciplinary rounds/meetings, use of notice boards, memos.	8 (6–9;3)	Partial consensus (high)
	28*	Minimise the use of verbal orders with provision of defined supporting processes, for example, preprinted templates, order sets.	8 (7–9;2)	Consensus (high)
Access to medications and resources	29	Provide a pharmacy-led service to ensure consistent, appropriate and safe access to a full range of medications appropriate to individual ICUs, for example, stock lists, regular top-up service, drug shortage management, defined storage locations, segregation of high-risk and sound-alike/look-alike medications.	9 (8–9;1)	Consensus (high)
	30	Source and supply medications in 'unit-dose' form with individual bar code where possible to support bar code medicines administration and closed-loop medication management.	6 (4–7;3)	Partial consensus (medium)
	31	Ensure all appropriate antidotes, reversal agents, rescue agents and relevant protocols are readily available.	9 (7–9;2)	Consensus (high)
	32	Maintain a comprehensive and easily accessible suite of up-to-date guidelines and reference sources, which are: approved at an organisational level; made available in digital format where possible; and with robust governance and version control measures in place.	8 (7–9;2)	Consensus (high)

*Only 18 participants responded to Recommendation 28.
ICU, intensive care unit.

panel member was asked to download and save their own responses. In subsequent rounds, this allowed panel members to see both their own response and that of the rest of the panel without knowing the identity of the other individuals providing scores or comments.

On completion of this, and subsequent rounds, a single reminder email with a link to the Delphi survey was sent to the panel prior to the stated deadline.

Subsequent Delphi Panel Rounds

Those recommendations for which consensus was not reached during previous rounds were progressed to subsequent rounds in an iterative manner. Recommendations were modified, where appropriate, based on the comments received during the previous round. An updated version of the online survey was devised specifically for each round. The original wording of any amended recommendations was included in the survey along with: the reworded recommendation, the median and IQR of the panel's scores, and any comments provided by individual panel members in the previous round.

In contrast to Delphi Round 1, subsequent rounds were conducted by email in consideration of geographical diversity and time constraints of individual Delphi panel members. Each participant received an email with a link to the survey and were asked to submit their scores using the online survey tool within 7 days of receipt of the email. The participants had the option to amend or retain their own Delphi Round 1 score having considered the group results of Delphi Round 1.

Results

Thirty-two initial policy recommendations (grouped into eight categories) to improve medication safety in ICUs across Europe were developed. Due to the anonymous participation, the backgrounds of the respondents cannot be described but details on the full EAHP SIG membership (n=21) are described above.

Delphi panel Round 1

The presentation for Round 1 of the Delphi panel took place on 13 October 2022. A total of 19 HCPs participated and all but one of the participants scored each of the 32 policy recommendations; one participant did not to respond to Recommendation #28. Consensus was achieved on 26 of the recommendations (table 1), with partial consensus on six recommendations (Recommendations 5, 6, 8, 13, 27 and 30). Disagreement was not found on any recommendation. Recommendations 4, 8 and 30 were considered as medium priority, with the remaining 29 considered to be of high priority.

The feedback received during Delphi Round 1 was used to modify, as appropriate, the wording of the six recommendations (Recommendations 5, 6, 8, 13, 27, 30) that had received partial consensus for Delphi Round 2. All but two (Recommendations 6 and 30) were reworded.

Delphi Panel Round 2

Eighteen HCPs provided their responses for Recommendations 8, 13 and 27, and 17 HCPs to Recommendation 30 (table 2) in the Delphi Round 2 survey sent by email to the panel on 15 November 2022. After this round was completed, a discrepancy in the calculation of the IQR of two recommendations in Delphi Round 1 data was identified. This was corrected and a supplementary Delphi Round 2b was arranged for prioritising Recommendations 5 and 6 (table 2); the original Round 2 was subsequently referred to as Delphi Round 2a. Seventeen HCPs responded to the Round 2b survey which was circulated by email on 6 December 2022. The participants classified all recommendations as 'high priority' with 'consensus' in the combined results for each portion of Delphi Round 2 (table 2).

Table 2 The consensus received for, and the priority given to, the policy recommendations in Delphi Rounds 2a and 2b by the Delphi panel of experts (n=18)*

No. (Delphi Round)	Original recommendation Delphi Round 1	New recommendation Delphi Round 2	Median (Q1–Q3; IQR)	Consensus (priority)
5 (2b)*	Undertake regular audits and self-assessment questionnaires, including measurement of patient safety climate in the ICU to monitor medication safety within the ICU.	Undertake regular audits and self-assessment questionnaires, including measurement of patient safety climate in the ICU, to inform improvement of medication safety within the ICU.	7.5 (6–8; 2)	Consensus (high)
6 (2b)*	Ensure adequate budget allocation to support sustained improvements in medication safety, including investment in human resources and appropriate technology in the ICU setting.	Unchanged	8 (7.5–9; 1.5)	Consensus (high)
8 (2a)	Implement automated dispensing cabinets for the storage of medications in the ICU.	Implement Automated Dispensing Cabinets for the storage of medications in the ICU, ensuring adequate resources for training, monitoring of usage and optimisation.	7 (5–7.25; 2.25)	Consensus (high)
13 (2a)	Identify and optimise all opportunities to integrate existing and future systems with the aim of providing 'closed loop' medication management, supporting the '5 rights' of medication administration.	Identify and optimise all opportunities to integrate existing and future systems with the aim of providing 'closed loop' medication management, minimising opportunities for error at each stage of the medication use process.	7 (6.75–8.25; 1.5)	Consensus (high)
27 (2a)	Promote interdisciplinary communication across entire medication use process, using a range of mechanisms and structures, for example, handover procedures and documentation, multidisciplinary rounds/meetings, use of notice boards, memos.	Ensure clear policies and processes are in place to support interdisciplinary communication across entire medication use process, for example, handover procedures and documentation, multidisciplinary rounds/meetings, use of notice boards, memos.	8 (6.75–9; 2.25)	Consensus (high)
30 (2a)*	Source and supply medications in 'unit-dose' form with individual bar code where possible to support bar code medicines administration and closed-loop medication management.	Unchanged	7 (4.5–7; 2.5)	Consensus (high)

*Only 17 participants responded to Recommendations 5, 6 and 30. ICU, intensive care unit.

Final policy recommendations on medication safety improvement in intensive care

After two Delphi Panel rounds, consensus was achieved on all 32 policy recommendations. All but one (Recommendation 4; medium priority) were considered as 'high priority'. Further Delphi Panel rounds were not required. The final recommendations are presented in table 3 along with a selection of supporting evidence from research studies, published policies or standards, and a summary of the relevant facilitators as identified from the focus group discussions conducted in one of the other SIG work packages.

DISCUSSION

A panel of HCPs from up to 13 different European countries have produced a consensus-based list of 32 policy recommendations for medication safety improvement in the intensive care setting. The high consensus levels and prioritisation of almost all of these recommendations are indicative of the need for safety initiatives to mitigate the risks, both perceived and evident from previously published research, associated with medication management in ICUs. The medication management process in the ICU is complex; a study in the paediatric ICU setting identified 30 subtasks as part of the prescribing process alone and how each of these needed to be completed correctly in order for the correct prescription to be written.³⁰ This complexity in the medication use process in tandem with the acuity of illness of the ICU patient cohort requires multifaceted risk mitigation strategies and interventions.³ We adopted a systems approach when developing these recommendations as we recognised that reducing the occurrence of MEs and promoting patient safety requires changes to the underlying system of care. This is apparent in the breadth of policy recommendations

over eight discrete categories ranging from the entire health system, to individual organisations, down to local ICU-level interventions and resources.

We have supplied examples of supporting literature for many of the policy recommendations as outlined in table 3, however, it has not been possible to provide an exhaustive list. An evidence base exists for many ME reduction strategies, for example, benefits of an ICU clinical pharmacy service²¹ and electronic prescribing,²⁴ but there is a gap in peer-reviewed evidence for others. In these cases, despite recommendations from individual professional bodies and patient safety organisations, robust evidence is still lacking. Reasons for this include the complexity of some of the proposed interventions, particularly those which are technology-based. Not only is successful implementation of these a significant undertaking requiring significant resources, but achieving and demonstrating intended benefits is also complex and difficult.³¹ The potential for unintended consequences and implications of changes in workflow also require consideration.³² Where research is conducted on these systems, comparing results from studies using different methodologies, disparate systems and levels of integration impedes generalisability of reported results. Despite this, use of technology in medication processes in European ICUs is increasing, as evidenced from the use of electronic prescribing, automated dispensing cabinets and 'smart-pumps', as reported in the survey conducted by the SIG in an earlier phase of this research.⁵ The consensus reached by the expert panel in this study provides further weight to support the need for investment in these solutions.

Many of the policy recommendations deemed to be high priority require few resources and should be more achievable in most ICUs. Although lower down on the Institute of

Table 3 Policy recommendations on medication safety improvements in the ICU setting

Category	Recommendation (ranked within categories by Delphi Priority Scores)	Supporting evidence	
		Facilitators for improving medication safety from EAHP SIG focus group	Refs
Organisational safety culture and working environment	Create and maintain an open, transparent and non-hierarchical 'no blame' culture supported by the ICU management to support staff in identifying, sharing, reporting and learning from incidents and near misses.	Open culture/interprofessional teamwork	1 12 15
	Implement an effective system to support the reporting of (medication-related) incidents and near misses, including mechanisms to provide feedback on reports to ICU staff.	Use of IT for example, incident reporting systems/engaging, giving feedback to, and communicating with, staff about incidents/safety	2 14
	Undertake routine, systematic and multidisciplinary review of all ICU-related incident reports to identify medication safety areas of risk, opportunities for improvement and provide feedback to ICU staff, for example, use of risk huddles.	Working interprofessionally/engaging, giving feedback to staff/incident reporting/auditing/researching medication safety	2
	Ensure adequate budget allocation to support sustained improvements in medication safety, including investment in human resources and appropriate technology in the ICU setting.	Funding/human resources/technology	1
	Ensure a safe working environment is provided for ICU staff to practise in a safe and efficient manner, for example, adequate lighting, avoidance of interruptions.	Management/resources	1 3
	Undertake regular audits and self-assessment questionnaires, including measurement of patient safety climate in the ICU, to inform improvement of medication safety within the ICU.	Auditing/researching medication safety	18
	Nominate a Medication Safety Lead within the ICU setting to work closely with the organisational Medication Safety Officer (or equivalent) where such a role exists on the implementation and promotion of medication error prevention strategies.	Medication safety pharmacist/team	8
Technology	Replace paper-based prescriptions with electronic prescribing systems, for example, computerised physician order entry, with associated clinical decision support appropriate to the ICU setting.	Use of IT systems	17 24
	Provide dedicated resources to facilitate the implementation, optimisation, maintenance and regular updates to all systems involved in medication management within the ICU.	Management/resources, for example, funding/human resources/use of IT systems	14
	Administer all medication infusions via programmable infusion pumps using 'Dose Error Reduction Software' or 'Smart-pumps', which contain a complete and regularly reviewed and updated drug library.	Use of IT systems	17 25
	Identify and optimise all opportunities to integrate existing and future systems with the aim of providing 'closed loop' medication management, minimising opportunities for error at each stage of the medication use process.	Management/use of IT systems/training/learning about medication safety	4 15
	Implement the use of bar-coded medication administration to reduce medication administration errors and support complete documentation.	Use of IT systems	4 17
	Ensure policies are in place to reduce workarounds and over-rides in the use of implemented technology, for example, bypassing smart-pump drug libraries, bar code medication administration workarounds and automated dispensing cabinet over-rides.	Management/use of IT systems/training/learning about medication safety	17 22
	Implement automated dispensing cabinets for the storage of medications in the ICU, ensuring adequate resources for training, monitoring of usage and optimisation.	Resources, for example, use of IT-systems / training/learning about medication safety	11 17
Clinical pharmacy	Provide a dedicated and specialised clinical pharmacy service to the ICU at a staffing level sufficient to ensure regular review and verification of all medications, attendance at multidisciplinary rounds and input into the development of policies, procedures and guidelines.	Working interprofessionally/human resources/pharmacists	14 21
	Adopt formal antimicrobial stewardship with multidisciplinary input to ensure appropriate use of antimicrobials and reduce antimicrobial resistance.	Working interprofessionally/national programmes/management/medication safety pharmacist/team	28
Education and training	Provide staff with protected time during working hours and access to a range of education and training opportunities in safe medication use to include new staff from all disciplines, new equipment/medications, refresher training and competency assessment.	Working interprofessionally/dedicated time/energy for training/learning/medication safety pharmacist/team	27
Intravenous medication management	Standardise and reduce the range of available/recommended medication infusion concentrations.	National programmes/management/medication safety pharmacist/team	9 16
	Provide supporting protocols and guidelines on preparation of intravenous medications as appropriate to the setting and availability of 'ready-to-administer' infusion solutions.	National programmes/management/medication safety pharmacist/team	26
	Minimise 'bedside' preparation of intravenous medications and replace with procured and centrally prepared 'ready-to-administer' or 'ready-to-use' medications wherever possible.	National programmes/management/pharmacists	9 16
	Ensure ease of access to information on intravenous compatibilities.	National programmes/management/medication safety pharmacist/team	
	Ensure processes are in place to support safe intravenous medication administration to include: appropriate labelling of medications and administration lines using targeted risk reduction strategies, for example, use of colours, TALLman lettering; administration line checks; infusion pump checks.	National programmes/management/medication safety pharmacist/team	17 22

Continued

Table 3 Continued

Category	Recommendation (ranked within categories by Delphi Priority Scores)	Supporting evidence	
		Facilitators for improving medication safety from EAHP SIG focus group	Refs
High-risk medication management	Ensure targeted and risk-assessed organisational policies and procedures are in place to support checking procedures for the preparation and administration of high-risk medications, for example, items requiring independent double-checking, specific labelling requirements.	National programmes/management/medication safety pharmacist/team	17 19
	Maintain a high-risk medication list that is reviewed regularly and is context-specific, for example, paediatrics, with a robust set of associated risk mitigation processes for all stages of the medication use process.	National programmes/management/medication safety pharmacist/team	17
Medication history and reconciliation	Employ standardised procedures, including patient, family and carer involvement as appropriate, to obtain and document an accurate and complete list (best possible medication history) of each patient's current medication on admission to the ICU.	National programmes/management/medication safety pharmacist/team/HCPs/patients	14 20
	Implement a formal and thorough medication reconciliation process on both admission to, and discharge from, the ICU to ensure accurate and comprehensive medication information is communicated consistently.	National programmes/management/medication safety pharmacist/team/HCPs/patients	4 10 14
	Minimise the use of verbal orders with provision of defined supporting processes, for example, pre-printed templates, order sets.	Working interprofessionally/national programmes/management/medication safety pharmacist/team	17
	Ensure clear policies and processes are in place to support interdisciplinary communication across entire medication use process, for example, handover procedures and documentation, multidisciplinary rounds/meetings, use of notice boards, memos.	Working interprofessionally/communicating with colleagues, national programmes /management/medication safety pharmacist/team/HCPs/patients	10
Access to medication and resources	Provide a pharmacy-led service to ensure consistent, appropriate and safe access to a full range of medications appropriate to individual ICUs, for example, stock lists, regular top-up service, drug shortage management, defined storage locations, segregation of high-risk and sound-alike/look-alike medications.	National programmes/management/human resources for example, pharmacists	14
	Ensure all appropriate antidotes, reversal agents, rescue agents and relevant protocols are readily available.	Management/resources/medication safety pharmacist/team	17
	Maintain a comprehensive and easily accessible suite of up-to-date guidelines and reference sources, which are: approved at an organisational level; made available in digital format where possible; and with robust governance and version control measures in place.	Management/resources/medication safety pharmacist/team/use of IT systems	27
	Source and supply medications in 'unit-dose' form with individual bar code where possible to support bar code medicines administration and closed-loop medication management.	Management/use of IT systems	13 23

EAHP, European Association of Hospital Pharmacists; HCP, healthcare professional; ICU, intensive care unit; SIG, Special Interest Group.

Safe Medication Practices Rank Order of Error Reduction Strategies, the use of good policy, procedures and provision of education and information to support staff in key areas such as management of high-risk and intravenous medications were considered high priority by the panel.³³ Standardisation, widely recognised by safety agencies as key to medication safety, was also identified as a priority. Although some of these strategies are more onerous to implement, for example, standard concentration infusions, with others reliant on conditions being met outside of individual organisations, for example, access to unit-dose medications, many are achievable within individual ICUs without substantial investment in terms of time or financial resources.

Strengths and limitations

A key strength of this study was the representation from 13 European countries covering the northern, southern and western regions of Europe. Utilisation of online meetings in addition to email—a modified version of the Delphi technique—facilitated this broad participation, while also allowing verbal clarification of understanding where necessary for non-native English speakers. Furthermore, use of purposive sampling in assembly of the EAHP SIG and the subsequent willingness to participate, ensured the panel composition included HCPs from various backgrounds in ICU settings and/or medication safety with relevant expertise. The range of resources used to develop the initial list

of recommendations, including both previous literature and new information as gathered from the survey and focus groups, provides confidence that both previously identified ME prevention strategies and perceptions of HCPs working in ICUs and within medication safety across Europe were incorporated. Limitations include identification of the recommendations from literature review and expert opinion, without measures of effectiveness based on quality of evidence, and the inability to stratify the recommendations on ease of implementation or requisite resources. Further limitations include lack of participation of HCPs from eastern Europe and over-representation by pharmacists. As with any Delphi panel study, there may be some response bias such as individuals with greater interest or expertise in medication safety being more likely to participate.

CONCLUSION

The Delphi technique was successfully used to develop and prioritise policy recommendations to enhance medication safety in ICUs in Europe. All recommendations, except one, were considered 'high priority' for implementation, indicative of the perceived value of these recommendations in improving medication safety by preventing MEs from occurring in ICUs. The results of this study can help inform individual ICUs in reviewing their local context and identifying priorities to improve medication safety.

What this paper adds

What is already known on this topic

- ⇒ The intensive care unit is a challenging setting for safe medication use.
- ⇒ Critically ill patients, high-risk interventions and the complex intensive care unit environment combine to increase the risk of medication errors.
- ⇒ Medication errors can occur across multiple points in the medication use process.

What this study adds

- ⇒ This study, which used evidence from literature and stakeholders, adopted a systems approach to develop 32 policy recommendations across eight categories.
- ⇒ Through the use of Delphi methodology, consensus and prioritisation of these recommendations was undertaken.

How this study might affect research, practice or policy

- ⇒ These recommendations can be used by intensive care units to develop strategies relevant to their context to improve medication safety practices.

Author affiliations

¹Departments of Pharmacy and Digital Health, Children's Health Ireland, Dublin, Ireland

²School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland

³School of Pharmacy, University College Cork, Cork, Ireland

⁴Pharmacy Department, Cork University Hospital, Cork, Ireland

⁵School of Pharmacy, University College London, London, UK

⁶Centre for Medication Safety and Service Quality, Pharmacy Department, Imperial College Healthcare NHS Trust, London, UK

⁷Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

Acknowledgements The authors thank Stephanie Kohl, Gonzalo Marzal-Lopez, Lena Sheehan and Sufian Muhammad for their support during the work of the SIG, and Anne Hiselius, Andreas Valentin, Emily Whittome and Samuel Garcia for their initial contribution to the work of the SIG.

Collaborators The EAHP Special Interest Group for the Investigation of Medication Errors in Intensive Care Units comprised of the following individuals: Angela Amigoni (Italy), Irene Aquerreta (Spain), Božena Bürmen (Slovenia), Andrea Burch (Switzerland), Claire Chapuis (France), Suzanne Cooper (United Kingdom), John Dade (United Kingdom), Bryony Dean Franklin (United Kingdom), Dylan W. De Lange (the Netherlands), Moninne Howlett (Republic of Ireland), Minna Kurttila (Finland), Raisa Laaksonen (Co-Chair of the SIG, Finland), Chiara Lamesta (Italy), Jana Lass (Estonia), Maria Cruz Martin (Spain), Suzanne McCarthy (Republic of Ireland), Virginia Silviri (Co-Chair of the SIG, Republic of Ireland), Inese Sviestina (Latvia).

Contributors MH is guarantor of this study and is responsible for overall content. MH and SM contributed equally to this paper and are first authors; they designed the study methodology and data collection tool, analysed the data, finalised the recommendations, and drafted and revised the paper. RL and VS conceptualised the study, contributed to the design of the study, monitored data collection and analysis, and revised the paper. BDF contributed to the design of the study and revised the paper. All members of the EAHP Special Interest Group for the Investigation of Medication Errors in Intensive Care Units contributed to the design of the study.

Funding The EAHP has received funding from BD (Becton, Dickinson and Company) for the running of the SIG. However, the SIG is independent of the pharmaceutical company providing research funding to the EAHP. BDF is supported by the National Institute for Health and Care Research (NIHR) North West London Patient Safety Research Collaboration and the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College in partnership with Public Health England (PHE). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, PHE or the Department of Health and Social Care.

Competing interests RL and VS are associate editors of the *European Journal of Hospital Pharmacy*. All other authors declare no competing interests.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the University of Helsinki Ethical Review Board in Humanities and Social and Behavioural Sciences (Statement: 18/2022). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request

ORCID iDs

Moninne Howlett <http://orcid.org/0000-0002-5798-6240>

Suzanne McCarthy <http://orcid.org/0000-0002-0695-7052>

Virginia Silviri <http://orcid.org/0000-0001-6637-7028>

Bryony Dean Franklin <http://orcid.org/0000-0002-2892-1245>

Raisa Laaksonen <http://orcid.org/0000-0003-3841-0534>

REFERENCES

- 1 World Health Organization. *Global patient safety action plan 2021-2030: towards eliminating avoidable harm in health care*. World Health Organization, 2021.
- 2 Brunsvelde-Reinders AH, Arbous MS, De Vos R, et al. Incident and error reporting systems in intensive care: a systematic review of the literature. *Int J Qual Health Care* 2016;28:2–13.
- 3 Moyon E, Camiré E, Stelfox HT. Clinical review: medication errors in critical care. *Crit Care* 2008;12:208.
- 4 Ciapponi A, Fernandez Nieves SE, Seijo M, et al. Reducing medication errors for adults in hospital settings. *Cochrane Database Syst Rev* 2021;11.
- 5 European Association of Hospital Pharmacists, EAHP. Special interest group report - the investigation of medication errors in intensive care units. 2023. Available: https://www.eahp.eu/sites/default/files/report_sig_for_the_investigation_of_medication_errors_in_intensive_care_units.pdf
- 6 Keeney S, Hasson F, McKenna H. The Delphi technique in nursing and health research. In: *The Delphi technique in nursing and health research*. John Wiley & Sons, 14 January 2011.
- 7 Jünger S, Payne SA, Brine J, et al. Guidance on conducting and reporting Delphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. *Palliat Med* 2017;31:684–706.
- 8 American Society of Health-System Pharmacists, ASHP. Statement on the role of the medication safety leader. 2019. Available: <https://www.ashp.org/-/media/assets/policy-guidelines/docs/statements/role-of-medication-safety-leader.ashx>
- 9 American Society of Health-System Pharmacists, ASHP. Standardize 4 safety. 2022. Available: <https://www.ashp.org/pharmacy-practice/standardize-4-safety-initiative?loginreturnUrl=SSOCheckOnly>
- 10 Bosma BE, Hunfeld NGM, Roobol-Meuwese E, et al. Voluntarily reported prescribing, monitoring and medication transfer errors in intensive care units in the Netherlands. *Int J Clin Pharm* 2021;43:66–76.
- 11 Chapuis C, Roustit M, Bal G, et al. Automated drug dispensing system reduces medication errors in an intensive care setting. *Crit Care Med* 2010;38:2275–81.
- 12 Dunstan E, Cook J-L, Coyer F. Safety culture in intensive care internationally and in Australia: A narrative review of the literature. *Aust Crit Care* 2019;32:524–39.
- 13 European Association of Hospital Pharmacists, EAHP. EAHP Statement on the Need for Barcoding of the Single Dose. 2012 Available: https://www.eahp.eu/sites/default/files/files/Barcode_2012%20pdf.pdf
- 14 European Association of Hospital Pharmacists, EAHP. European statements of hospital Pharmacy. 2014. Available: <https://www.eahp.eu/hp-practice/hospital-pharmacy/european-statements-hospital-pharmacy>
- 15 European Association of Hospital Pharmacists, EAHP. Position paper on patient safety: hospital pharmacists – making the difference by improving medication safety. 2020. Available: https://www.eahp.eu/sites/default/files/eahp_position_paper_on_patient_safety_october_2020.pdf
- 16 Hedlund N, Beer I, Hoppe-Tichy T, et al. Systematic evidence review of rates and burden of harm of intravenous admixture drug preparation errors in Healthcare settings. *BMJ Open* 2017;7:e015912.
- 17 Institute for Safe Medication Practices (ISMP). ISMP targeted medication safety best practices for hospitals. 2022. Available: <https://www.ismp.org/guidelines/best-practices-hospitals>
- 18 Institute for Safe Medication Practices (ISMP). ISMP medication safety self assessments. 2023. Available: <https://www.ismp.org/self-assessments>
- 19 Koyama AK, Maddox C-SS, Li L, et al. Effectiveness of double checking to reduce medication administration errors: a systematic review. *BMJ Qual Saf* 2020;29:595–603.
- 20 Kram BL, Trammel MA, Kram SJ, et al. Medication histories in critically ill patients completed by Pharmacy personnel. *Ann Pharmacother* 2019;53:596–602.
- 21 Lee H, Ryu K, Sohn Y, et al. Impact on patient outcomes of pharmacist participation in Multidisciplinary critical care teams: A systematic review and meta-analysis. *Crit Care Med* 2019;47:1243–50.
- 22 Melia D, Saha S. Minimising prescribing errors in the ICU. *Crit Care* 2014;18.

- 23 Morriss FH Jr, Abramowitz PW, Nelson SP, *et al.* Effectiveness of a Barcode medication administration system in reducing preventable adverse drug events in a neonatal intensive care unit: a prospective cohort study. *J Pediatr* 2009;154:363–8.
- 24 Prgomet M, Li L, Niazkhani Z, *et al.* Impact of commercial computerized provider order entry (CPOE) and clinical decision support systems (Cdss) on medication errors, length of stay, and mortality in intensive care units: a systematic review and meta-analysis. *J Am Med Inform Assoc* 2017;24:413–22.
- 25 Skog J, Rafie S, Schnock KO, *et al.* The impact of smart pump Interoperability on errors in intravenous infusion administrations: A Multihospital before and after study. *J Patient Saf* 2022;18:e666–71.
- 26 Sutherland A, Jones MD, Howlett M, *et al.* Developing strategic recommendations for implementing smart pumps in advanced Healthcare systems to improve intravenous medication safety. *Drug Saf* 2022;45:881–9.
- 27 The Health Information and Quality Authority (HIQA). National standards for safer better Healthcare. 2012. Available: <https://www.hiqa.ie/sites/default/files/2017-01/Safer-Better-Healthcare-Standards.pdf>
- 28 World Health Organization. *Global antimicrobial resistance surveillance system (GLASS) report: early implementation*. 2020.
- 29 Howlett MM, Cleary BJ, Breatnach CV. Defining novel medication errors introduced by the use of health information technology in Paediatric critical care – A modified Delphi process. *Arch Dis Child* 2018;18.
- 30 Sutherland A, Ashcroft DM, Phipps DL. Exploring the human factors of prescribing errors in Paediatric intensive care units. *Arch Dis Child* 2019;104:588–95.
- 31 McCarthy S, Laaksonen R, Silviri V. Transition of care from adult intensive care settings – implementing interventions to improve medication safety and patient outcomes. *BMJ Qual Saf* 2022;31:565–8.
- 32 Adams KT, Pruitt Z, Kazi S, *et al.* Identifying health information technology usability issues contributing to medication errors across medication process stages. *J Patient Saf* 2021;17:e988–94.
- 33 Institute for Safe Medication Practices. Education is predictably disappointing and should never be relied upon alone to improve safety. 2020. Available: <https://www.ismp.org/resources/education-predictably-disappointing-and-should-never-be-relied-upon-alone-improve-safety>